The importance of characterizing unbinding kinetics is increasingly recognized in drug discovery. Understanding the on-target residence time of a drug can lead to safer and more effective medications. By mitigating liabilities such as suboptimal efficacy and potential toxicity, it is possible to improve the therapeutic window of drug candidates. Residence time also determines the speed at which assays reach equilibrium, and in turn, the time needed to accurately measure equilibrium quantities. In addition, the residence time of a drug bound to its protein target has been occasionally shown to be a better determinant of in vivo efficacy than the equilibrium quantities measured in vitro in the course of the preclinical drug discovery process. Measuring and accurately predicting drug-unbinding kinetics has received significant attention in recent years, as evidenced by research community efforts have been carried out via the Kinetics for Drug Discovery (K4DD) Consortium to provide a deeper understanding of this process.